DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its President and CEO, David Bupp, will present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference on Monday, March 15, 2010 at 4:00 PM PST. The conference is taking place at the Ritz-Carlton in Laguna Niguel, CA. Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical and regulatory status of Neoprobe’s two drug development products, Lymphoseek® and RIGScan™ CR.
